Skip to content
Sign in
StableHealthReported 2026-11-11 12:05

PIMJETMI® (pimicotinib) Receives FDA Approval for TGCT

PIMJETMI® (pimicotinib), developed by Abbisko Therapeutics and licensed by Merck KGaA, received FDA approval for treating symptomatic tenosynovial giant cell tumor (TGCT) in the U.S., marking the fourth global approval for the drug.

Why it matters. Patients with TGCT now have a new systemic treatment option, improving their quality of life and mobility.

01

Who and what it touches

China National Medica…regulated byHealth Canadaregulated bySwiss Agency for Ther…regulated byUS Food and Drug Admi…regulated byPIMJETMI (pimic…

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • PPR Newswire news releasesCompany2026-11-11 12:05
    In December 2023, Abbisko entered into an agreement with Merck KGaA, Darmstadt, Germany, pertaining to the commercial rights to pimicotinib
    View source
  • GGDELT Global Knowledge GraphMedia2026-11-11 13:00
    View source